Phase II Trial of Weekly Paclitaxel and Carboplatin Chemotherapy in Patients with Advanced Transitional Cell Cancer

Combination therapy using weekly paclitaxel and carboplatin was active in patients with advanced TCC and adverse prognostic features. The weekly dosing used in this trial warrants further investigation as an alternative first-line approach in patients with poor renal reserve and/or performance status or as a second-line management of advanced TCC.